The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre
Summary: Zonisamide (ZNS) is an antiepileptic drug (AED) with multiple putative mechanisms of action. It is chemically unrelated to other AEDs. It has been available in Japan since 1989 but was only licensed in Europe in 2005. Its efficacy and tolerability have been shown in several randomised controlled trials, but large studies on long-term performance in Western clinical practice are scarce.We assessed a large cohort of consecutive people who started ZNS at a tertiary epilepsy referral centre, from June 2005 to July 2009.Forty-six percent of the 417 people included were still taking ZNS at last follow-up, with an estimated retention rate at three years of 30%. Almost one third of the population reported a period of improvement in terms of seizure reduction of at least six months duratio...
When to Start ART? More DataWhen to Start ART? More Data
Paul E. Sax, MD, describes a new study providing guidance on when to start ART in HIV, based on CD4 cell counts. Medscape HIV/AIDS (Source: Medscape Today Headlines)
